Immuron Secures upto $1.7M Equity & Convertible Note Funding
Filed with ASX · · 2 pages · English
Earlier from Immuron
- Immuron Receives $1.47M R&D Tax Concession Refund
- Analyst Reports on Immuron IMM-529 C. difficile Program
Later from Immuron
- Immuron Initiates Pre-Clinical Colitis Development Program
- Appendix 4D - Half Yearly Report and Accounts
- Immuron Improves Hadasit Royalty Terms
- Expansion of US Travelan Sales Following CVS Pharmacy Launch
- US Travelan Sales Network Widened by Allocation Inc Ptnrship
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron